Viromed Medical Completes Study on Cold Plasma for Lung Infections, Shows Promise in Ventilator-Associated Pneumonia

Viromed Medical AG, a medical technology company specializing in cold plasma technology, announced the successful completion of a multi-year study on the application of cold atmospheric plasma (CAP) in the lung. The study data will be submitted for publication in a renowned scientific journal, marking a significant milestone for the company and the field of pneumology.

The research focused on ventilator-associated pneumonia (VAP), a critical challenge in intensive care medicine. The results confirm the potential of cold plasma as a physical, non-pharmacological treatment option for severe infectious lung diseases. The data demonstrate a clearly defined therapeutic safety window and complete reduction of pathogenic germs in lung epithelial models. An important component was the ex vivo validation on vital lungs in collaboration with Saarland University and Hannover Medical School, using an isolated, ventilation- and perfusion-capable lung model that realistically reflects key physiological characteristics of the human lung.

Uwe Perbandt, Member of the Management Board of Viromed Medical AG, stated, “By successfully completing this study, we have reached a point of outstanding importance for Viromed and for modern pneumology. The data confirm the potential of our cold plasma technology in one of the most sensitive organ systems of the human body. It is particularly encouraging that we are no longer speaking only about preclinical evidence, but are already seeing first successful applications in patients in a university clinical setting.”

Based on the study results, Viromed’s technology has already been used in a university hospital setting for a severe pulmonary individual case involving a lung transplant patient with massive complications. Following ethics committee approval, the use of cold plasma was very successful, with treating physicians noting the observed positive clinical course was exceptional. The hospital plans to publish the case soon, and further severely ill patients with high risk of fatal outcomes are undergoing treatment.

Viromed sees clear indications that cold plasma technology will fundamentally change pneumology. While classical pharmacological therapies are increasingly limited by antimicrobial resistance, cold plasma’s physical mode of action opens a new therapeutic dimension, including prevention of severe pulmonary infections. Looking ahead, further applications in intensive care medicine are moving into clinical research, such as intracardiac use in operations for bacterial endocarditis or application in the thorax for bacterial pleural empyema.

More information about Viromed Medical AG can be found at www.viromed-medical-ag.de. The original press release is available on www.newmediawire.com.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Viromed Medical Completes Study on Cold Plasma for Lung Infections, Shows Promise in Ventilator-Associated Pneumonia.

The post Viromed Medical Completes Study on Cold Plasma for Lung Infections, Shows Promise in Ventilator-Associated Pneumonia appeared first on citybuzz.